Analysis of the current status of patient registry studies in China

Objective To analyze the current status of patient registry studies conducted in China, and to provide reference basis for improvement of patient registry studies.Methods Patient registry studies in China were searched in ClinicalTrials.gov, and the time limit for searching was from the establishmen...

Full description

Saved in:
Bibliographic Details
Main Authors: YI Hongbin, NIE Zhifeng, HAN Sheng, SHI Luwen
Format: Article
Language:zho
Published: Editorial Office of New Medicine 2025-05-01
Series:Yixue xinzhi zazhi
Subjects:
Online Access:https://yxxz.whuznhmedj.com/futureApi/storage/attach/2505/2rL6qFLxNIcI6SQIP0GiQc1oTOJX6iW0WBhgtRMn.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850125248524976128
author YI Hongbin
NIE Zhifeng
HAN Sheng
SHI Luwen
author_facet YI Hongbin
NIE Zhifeng
HAN Sheng
SHI Luwen
author_sort YI Hongbin
collection DOAJ
description Objective To analyze the current status of patient registry studies conducted in China, and to provide reference basis for improvement of patient registry studies.Methods Patient registry studies in China were searched in ClinicalTrials.gov, and the time limit for searching was from the establishment of the database to June 2024. The descriptive analyses was carried out to evaluate the situation, the scale, the main disease of the sponsors and funders of patient registry studies in China.Results As of June 2024, there were a total of 1,565 patient registry studies in China registered on ClinicalTrials.gov. The results showed that the sponsors of patient registry studies in China were mainly hospitals, universities and other institutions, of which the Peking Union Medical College Hospital had the largest number of sponsors (64, 4.09%). A total of 1,441 patient registry studies in China were funded by "other", accounting for 92.08%. Most of the patient registry studies were under the process of recruitment (565, 36.10%). Most of the patient registry studies had 100~999 enrolled cases (713, 45.56%). The main disease area involved were cancer (186, 11.88%), stroke (81, 5.18%) and heart disease (53, 3.39%).Conclusion Patient registry studies in China are developing well, gradually increasing in number, covering a wide range of disease areas, with active participation of hospitals and universities. However, there are still problems and challenges such as insufficient management and transparency, limited scale of research, and single source of funding.
format Article
id doaj-art-fe0895594cd9493386b72c3e844ab6f5
institution OA Journals
issn 1004-5511
language zho
publishDate 2025-05-01
publisher Editorial Office of New Medicine
record_format Article
series Yixue xinzhi zazhi
spelling doaj-art-fe0895594cd9493386b72c3e844ab6f52025-08-20T02:34:09ZzhoEditorial Office of New MedicineYixue xinzhi zazhi1004-55112025-05-0135549149610.12173/j.issn.1004-5511.2024121516642Analysis of the current status of patient registry studies in ChinaYI HongbinNIE ZhifengHAN ShengSHI LuwenObjective To analyze the current status of patient registry studies conducted in China, and to provide reference basis for improvement of patient registry studies.Methods Patient registry studies in China were searched in ClinicalTrials.gov, and the time limit for searching was from the establishment of the database to June 2024. The descriptive analyses was carried out to evaluate the situation, the scale, the main disease of the sponsors and funders of patient registry studies in China.Results As of June 2024, there were a total of 1,565 patient registry studies in China registered on ClinicalTrials.gov. The results showed that the sponsors of patient registry studies in China were mainly hospitals, universities and other institutions, of which the Peking Union Medical College Hospital had the largest number of sponsors (64, 4.09%). A total of 1,441 patient registry studies in China were funded by "other", accounting for 92.08%. Most of the patient registry studies were under the process of recruitment (565, 36.10%). Most of the patient registry studies had 100~999 enrolled cases (713, 45.56%). The main disease area involved were cancer (186, 11.88%), stroke (81, 5.18%) and heart disease (53, 3.39%).Conclusion Patient registry studies in China are developing well, gradually increasing in number, covering a wide range of disease areas, with active participation of hospitals and universities. However, there are still problems and challenges such as insufficient management and transparency, limited scale of research, and single source of funding.https://yxxz.whuznhmedj.com/futureApi/storage/attach/2505/2rL6qFLxNIcI6SQIP0GiQc1oTOJX6iW0WBhgtRMn.pdfpatient registry studyregistry studystatus analysis
spellingShingle YI Hongbin
NIE Zhifeng
HAN Sheng
SHI Luwen
Analysis of the current status of patient registry studies in China
Yixue xinzhi zazhi
patient registry study
registry study
status analysis
title Analysis of the current status of patient registry studies in China
title_full Analysis of the current status of patient registry studies in China
title_fullStr Analysis of the current status of patient registry studies in China
title_full_unstemmed Analysis of the current status of patient registry studies in China
title_short Analysis of the current status of patient registry studies in China
title_sort analysis of the current status of patient registry studies in china
topic patient registry study
registry study
status analysis
url https://yxxz.whuznhmedj.com/futureApi/storage/attach/2505/2rL6qFLxNIcI6SQIP0GiQc1oTOJX6iW0WBhgtRMn.pdf
work_keys_str_mv AT yihongbin analysisofthecurrentstatusofpatientregistrystudiesinchina
AT niezhifeng analysisofthecurrentstatusofpatientregistrystudiesinchina
AT hansheng analysisofthecurrentstatusofpatientregistrystudiesinchina
AT shiluwen analysisofthecurrentstatusofpatientregistrystudiesinchina